Plasmodium therapy also inhibits the expression of signaling molecules that recruit immunosuppressive cells (such as MDSCs, Tregs, TAMs, and so on) into tumor tissues, and inhibit the function of these immunosuppressive cells (for example, the secretion of IL-10 and TGF-β), thereby systemically counteracting the tumor immunosuppressive microenvironment. This evidence concerns the gene TGFB1 and neoplasm.